While the efficacy of midostaurin and quizartinib for remission maintenance in FLT3-mutated AML remains to be formally validated, oral azacitidine and HDC/IL-2 were only administered after the completion of chemotherapy in the pivotal phase III trials (QUAZAR and 0201, respectively) ascertaining that these regimens prevent relapse in the postchemotherapy phase. Here, FLT3 is linked to acute myeloid leukemia.